Liposomal encapsulation of foscarnet protects against hypocalcemia induced by free foscarnet.

Hypocalcemia and an increase in creatinine level are the most important serious effects associated with foscarnet (PFA) therapy. In an animal model, we have explored the potential protective role of liposome-encapsulated foscarnet (LE-PFA) on these metabolic abnormalities. PFA administered as one bo...

全面介紹

書目詳細資料

發表在:	Antimicrob Agents Chemother
Principais autores:	Omar, R F, Dusserre, N, Désormeaux, A, Poulin, L, Tremblay, M, Beauchamp, D, Bergeron, M G
格式:	Artigo
語言:	Inglês
出版:	American Society for Microbiology (ASM) 1995
主題:	Research Article
在線閱讀:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC162866/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/8540701/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.39.9.1973
標簽:	添加標簽 沒有標簽, 成為第一個標記此記錄!